[{"orgOrder":0,"company":"TrialSpark","sponsor":"resTORbio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Dactolisib","moa":"TORC1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TrialSpark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TrialSpark \/ resTORbio","highestDevelopmentStatusID":"10","companyTruncated":"TrialSpark \/ resTORbio"}]

Find Infections and Infectious Diseases Clinical Drug Pipeline Developments & Deals by TrialSpark

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AGGSpend
                          Not Confirmed
                          AGGSpend
                          Not Confirmed

                          Details : TrialSpark's integrated tech platform and trial model will enable resTORbio to accelerate their clinical trials of RTB-101 for COVID-19 in community/outpatient settings.

                          Product Name : RTB101

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 28, 2020

                          Lead Product(s) : Dactolisib

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : resTORbio

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank